Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.

No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.

Non-hodgkin Lymphoma

Dietary intervention with or without seed mix

Milled seed mix

Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade

Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma

Effects of Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma

Changes in body weight measured by bio-impedance analyzer, from baseline to endpoint

Changes in lipid profiles (cholesterol, HDL, LDL and triglycerides) from baseline to endpoint

Changes in plasma fatty acids profiles from baseline to endpoint

Changes in interleukin (IL)-6 from baseline to endpoint

Measures of activities of the following enzymes: SOD, catalase, glutathion peroxidase and glutation reductase

Vesna Vucic

Professor of Research

University of Belgrade

This study is a parallel, randomized, single blind, controlled, 5-months nutritional intervention, investigating health effects of dietary intake of milled mix of flax/sesame pumpkin seeds in sour milk, in patients with NHL undergoing chemotherapy.
At the beginning of the study, all patients received nutritional counselling, where half of the study subjects are randomly assigned to a treatment arm with milled seed mix consumption, or control arm without seed mix. Treatment arm is provided with 450g of milled seed mix and instructed to consume 30g of the mix daily (18g flax seed, 6g pumpkin seeds, and 6 g sesame) in 180 mL of sour milk. Control arm is instructed to consume180 mL of sour milk.

Hemodialysis

University of Utah

Dialysis Registry in Utah

The objective is to develop a registry of incident dialysis patients at the University of Utah dialysis program

Srinvasan Beddhu

Insomnia

Depression

Inflammation

Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period

cognitive behavioral therapy

Far Eastern Memorial Hospital

Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis

Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis and Its Impacts on Their Inflammatory Cytokines, Oxidative Stress and Autonomic Dysfunction

Anemia

Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.
Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen.

Peginesatide

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

A Phase 1, Multicenter, Open-Label Dose Escalation Study Evaluating the Safety and Tolerability of Multiple Hematide Injections in Subjects With Refractory Non-Small Cell Lung Cancer, Breast Cancer, or Prostate Cancer Who Are Anemic and Receiving Cytotoxic Chemotherapy

hemodialysis/breast neoplasms

Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma

Dialysis Registry in Utah

Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Den mest komplette databasen med medisinske urter støttet av vitenskap